Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/1499
Full metadata record
DC FieldValueLanguage
dc.contributor.authorXayrullayeva Sa'namxon Sagdullayevna, Rustamova Mamlakat Tulyabaevna,-
dc.date.accessioned2025-05-23T05:06:03Z-
dc.date.available2025-05-23T05:06:03Z-
dc.date.issued2025-
dc.identifier.issn2010-7773-
dc.identifier.urihttp://repo.tma.uz/xmlui/handle/1/1499-
dc.description.abstractThe article presents data on the results of a comparative study of the clinical and anti-Helicobacter efficacy of two eradication therapy regimens in 60 patients with Helicobacter Pylori (HP)-associated chronic gastritis. The main group of patients received eradication therapy consisting of vonoprazan, amoxicillin, clarithromycin, and bismuth tripotassium decitrate for 10 days. The second group of patients received esomeprazole as an antisecretory drug against the background of similar therapy. It was shown that in the first group of patients, the dynamics of acid suppression under the influence of vonoprazan was significantly higher compared to esomeprazole. In the main group of patients, the eradication rate of HP infection was 93%, and in the group of patients taking esomeprazole, this figure was 80%.en_US
dc.language.isootheren_US
dc.publisher"O‘zbekiston vrachlar assotsiatsiyasi"en_US
dc.subjectvonoprazan, potassium-competitive acid blocker, Helicobacter pylori, chronic gastritis, eradication.en_US
dc.title"КОМПЛЕКСНАЯ ЭРАДИКАЦИОННАЯ ТЕРАПИЯ C ВКЛЮЧЕНИЕМ ВОНОПРАЗАНА У БОЛЬНЫХ С ХРОНИЧЕСКИМИ ГАСТРИТАМИ, АССОЦИИРОВАННЫМИ HELICOBAKTER PYLORI"en_US
dc.typeArticleen_US
Appears in Collections:Articles



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.